<DOC>
	<DOCNO>NCT00006484</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness carboplatin plus paclitaxel without tirapazamine treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Tirapazamine Treating Patients With Stage IIIB Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect paclitaxel carboplatin without tirapazamine progression-free survival overall survival patient stage IV select stage IIIB non-small cell lung cancer . - Compare response rate patient treat regimen . - Compare toxic effect regimens patient . OUTLINE : This randomize study . Patients stratify accord weight loss ( le 5 % vs 5 % ) , stage disease ( IIIB v IV ) , lactate dehydrogenase level ( normal v abnormal ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive tirapazamine IV 2 hour follow paclitaxel IV 3 hour carboplatin IV 30 minute day 1 . - Arm II : Patients receive paclitaxel carboplatin arm I . Treatment continue every 21 day total 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month one year , every 6 month 2 year , death . PROJECTED ACCRUAL : Approximately 500 patient ( 250 per arm ) accrue study within 20 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven newly diagnose advanced primary nonsmall cell lung cancer ( NSCLC ) , include follow cellular type : Adenocarcinoma Large cell carcinoma Squamous cell carcinoma Unspecified carcinoma OR Recurrent disease prior surgery and/or radiotherapy Stage IIIB disease T4 lesion due malignant pleural effusion OR Stage IV disease Any T , N , M1 ( distant metastasis , include lesion multiple lobes ipsilateral lung ) Measurable evaluable disease Pleural effusion , ascites , laboratory parameter consider evidence disease Must outside prior radiated field area prior surgical resection new lesion must present No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN Alkaline phosphatase great 2 time ULN Renal : Creatinine great ULN Creatinine clearance least 50 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception No peripheral neuropathy ( motor sensory ) grade 2 great No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , stage I/II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy NSCLC Chemotherapy : No prior systemic chemotherapy NSCLC Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics At least 2 week since prior thoracic major surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>